Loading...
Market
What percentage of patients will experience significant improvement with KarXT by the end of 2025?
2
Resolution / Starting Odds
Less than 20% • 25%
20% to 30% • 25%
31% to 40% • 25%
More than 40% • 25%
Published clinical trial results or peer-reviewed studies
Story
KarXT by Bristol Myers Squibb: First Novel Schizophrenia Drug in 70 Years Shows 30% Symptom Improvement for 1 in 300 People
Oct 17, 2024, 12:00 PM
KarXT, a new oral medication developed by Bristol Myers Squibb (BMS), aims to be the first significant advancement in schizophrenia treatment in over 70 years. This twice-daily pill is designed to address the severe mental health condition that affects approximately 1 in 300 people globally. Early reports indicate that patients using KarXT are experiencing a 30% improvement in symptoms, while also avoiding the severe side effects commonly associated with older schizophrenia medications. The development of KarXT has been supported by research funded by the Wellcome Trust, highlighting the potential for pharmaceutical innovation to enhance treatment options for millions affected by this condition.
View original story
Similar markets
< 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
> 30% • 25%
Less than 10% • 25%
10% to 19% • 25%
20% to 29% • 25%
30% or more • 25%
Significant improvement • 25%
Moderate improvement • 25%
No improvement • 25%
Negative impact • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Less than 50% • 25%
50% to 70% • 25%
71% to 90% • 25%
More than 90% • 25%